Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

CLSD

Clearside Biomedical Inc

May 03 • 04:00PM ET

1.31

Dollar change -0.01
Percentage change -0.76	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.53	Insider Own	15.82%	Shs Outstand	74.72M	Perf Week	-2.24%
Market Cap	97.88M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	4.82%	Shs Float	62.90M	Perf Month	-1.50%
Income	-32.48M	PEG	-	EPS next Q	-0.14	Inst Own	16.68%	Short Float	0.42%	Perf Quarter	-4.38%
Sales	8.23M	P/S	11.89	EPS this Y	0.89%	Inst Trans	-7.09%	Short Ratio	0.71	Perf Half Y	71.69%
Book/sh	-0.25	P/B	-	EPS next Y	-10.28%	ROA	-76.15%	Short Interest	0.27M	Perf Year	31.63%
Cash/sh	0.39	P/C	3.38	EPS next 5Y	-	ROE	-1310.02%	52W Range	0.65 - 2.12	Perf YTD	11.97%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.88%	ROI	-121.55%	52W High	-38.21%	Beta	2.36
Dividend TTM	-	Quick Ratio	4.42	Sales past 5Y	1621.13%	Gross Margin	94.87%	52W Low	101.51%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	4.42	EPS Y/Y TTM	3.80%	Oper. Margin	-302.02%	RSI (14)	47.22	Volatility	6.50% 9.61%
Employees	30	Debt/Eq	-	Sales Y/Y TTM	519.89%	Profit Margin	-394.91%	Recom	1.00	Target Price	5.40
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	51.62%	Payout	-	Rel Volume	0.26	Prev Close	1.32
Sales Surprise	43.12%	EPS Surprise	9.40%	Sales Q/Q	1822.73%	Earnings	Mar 12 AMC	Avg Volume	374.69K	Price	1.31
SMA20	1.31%	SMA50	-9.70%	SMA200	13.79%	Trades		Volume	98,534	Change	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-15-21	Resumed	Wedbush	Outperform	$19 → $9
Jul-29-21	Initiated	H.C. Wainwright	Buy	$10
May-13-20	Initiated	ROTH Capital	Buy	$8
Aug-09-19	Downgrade	Needham	Buy → Hold
Nov-05-18	Downgrade	Stifel	Buy → Hold
Nov-05-18	Downgrade	JP Morgan	Overweight → Underweight
Nov-05-18	Downgrade	Cowen	Outperform → Market Perform
Mar-06-18	Reiterated	Needham	Buy	$18 → $22
May-25-17	Initiated	JMP Securities	Mkt Outperform	$21
Feb-24-17	Initiated	JP Morgan	Overweight	$19
Nov-10-16	Reiterated	Needham	Buy	$16 → $24
Oct-24-16	Reiterated	Stifel	Buy	$13 → $23

Show Previous Ratings

Apr-30-24 07:05AM	Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-16-24 07:05AM	Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors (GlobeNewswire) -10.85%
Apr-02-24 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -11.39%
Mar-18-24 07:05AM	Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer (GlobeNewswire) -8.77%
Mar-13-24 08:30AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:38AM	Loading…
06:38AM	Q4 2023 Clearside Biomedical Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 05:35PM	Clearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ... (GuruFocus.com) -18.81%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 02:25PM	These 2 Strong Buy Penny Stocks Could Surge Over 200%, Say Analysts (TipRanks) +8.63%
Feb-29-24 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 (GlobeNewswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-07-24 08:00AM	Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering (GlobeNewswire)
Dec-14-23 07:05AM	Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD (GlobeNewswire)
Nov-14-23 09:11AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Loading…
Nov-08-23 07:05AM	Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference (GlobeNewswire) -9.65%
Nov-07-23 04:20PM	Clearside Biomedical's Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector (GlobeNewswire) +19.39%
Nov-02-23 07:05AM	Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 07:05AM	Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD (GlobeNewswire) +5.30%
Oct-31-23 07:05AM	Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023 (GlobeNewswire) +5.17%
Oct-26-23 12:24AM	3 Cheap Stocks to Buy Under $1 in October 2023 (InvestorPlace) -5.28%
Oct-16-23 07:05AM	Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting (GlobeNewswire)
Oct-04-23 09:00AM	Clearside Biomedical Announces Advancement of XIPERE in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China (GlobeNewswire)
Oct-03-23 04:35PM	Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Sep-19-23 07:05AM	Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-23 04:05PM	Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:30PM	Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023 (GlobeNewswire)
Aug-01-23 07:05AM	Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023 (GlobeNewswire)
Jul-31-23 07:05AM	Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting (GlobeNewswire)
07:05AM	Loading…
Jul-20-23 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings (GlobeNewswire)
Jul-11-23 04:05PM	Clearside Biomedical CEO George Lasezkay to Present at the SHARE Series Investor Event on Monday, July 17, 2023 (GlobeNewswire)
Jul-10-23 07:05AM	Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema (GlobeNewswire)
Jun-29-23 09:50AM	We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate (Simply Wall St.)
Jun-01-23 07:05AM	Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
May-11-23 08:25AM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.90%
07:05AM	Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:30PM	Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-02-23 07:05AM	Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023 (GlobeNewswire)
Apr-27-23 07:05AM	Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-18-23 07:05AM	Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Apr-12-23 07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.48%
Apr-09-23 09:42AM	Clearside Biomedical (NASDAQ:CLSD) adds US$12m to market cap in the past 7 days, though investors from five years ago are still down 88% (Simply Wall St.)
Apr-05-23 07:05AM	Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians (GlobeNewswire) -8.89%
Mar-11-23 03:14AM	Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 06:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-23 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023 (GlobeNewswire) -5.26%
Feb-21-23 07:05AM	Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings (GlobeNewswire)
Feb-07-23 07:05AM	Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023 (GlobeNewswire)
Feb-06-23 07:30AM	Clearside Biomedical Announces Leadership Team Update (GlobeNewswire)
Feb-02-23 01:18PM	Clearside Biomedical Touts Encouraging Durable Data From Investigational Candidate For Vision Disorder (Benzinga)
07:05AM	Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD (GlobeNewswire)
Dec-22-22 09:52AM	2 Strong Buy Penny Stocks That Could Go Boom (TipRanks) +8.00%
05:05AM	Companies Like Clearside Biomedical (NASDAQ:CLSD) Can Afford To Invest In Growth (Simply Wall St.)
Nov-22-22 07:05AM	Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022 (GlobeNewswire)
Nov-11-22 05:26AM	Clearside Biomedical Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 01:24PM	Analyst Bumps Up Clearside Biomedical Target Price After Encouraging Trial Data (Benzinga)
07:05AM	Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference (GlobeNewswire)
Nov-09-22 09:05AM	Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.57%
07:15AM	Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
07:05AM	Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients (GlobeNewswire)
Nov-08-22 04:05PM	Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 07:05AM	Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022 (GlobeNewswire) +11.57%
Oct-31-22 08:52AM	Investors in Clearside Biomedical (NASDAQ:CLSD) have unfortunately lost 84% over the last five years (Simply Wall St.)
Oct-17-22 11:27AM	Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire) +14.17%
Sep-27-22 07:05AM	Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting (GlobeNewswire)
Aug-25-22 07:05AM	Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022 (GlobeNewswire)
Aug-11-22 06:21AM	These Analysts Think Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Sales Are Under Threat (Simply Wall St.)
Aug-09-22 08:35AM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-22 04:30PM	Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million (GlobeNewswire)
08:05AM	ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-03-22 07:05AM	Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022 (GlobeNewswire)
Jul-27-22 07:05AM	Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022 (GlobeNewswire)
Jul-26-22 07:05AM	Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients (GlobeNewswire)
Jul-09-22 08:25AM	Here's What Clearside Biomedical, Inc.'s (NASDAQ:CLSD) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-07-22 07:05AM	Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings (GlobeNewswire) +7.80%
Jun-14-22 07:05AM	Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer (GlobeNewswire)
Jun-08-22 07:05AM	Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 05:25PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -7.64%
04:05PM	Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-22 07:05AM	Clearside Biomedical Poster Presentation at ARVO 2022 Annual Meeting Demonstrates Versatility of Suprachoroidal Delivery Technology (GlobeNewswire) -6.13%
Apr-29-22 07:05AM	Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022 (GlobeNewswire) -5.56%
Apr-11-22 07:44AM	Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar? (Zacks)
Apr-06-22 07:05AM	Clearside Biomedical to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-22 06:59AM	Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis (PR Newswire)
Mar-15-22 06:38PM	Clearside Stock Is up Over 80% In Three Trading Days. How Much Higher Can It Go? (TipRanks) +19.71%
Mar-10-22 05:25PM	Clearside Biomedical, Inc. (CLSD) Q4 Earnings and Revenues Beat Estimates (Zacks) -9.40%
04:05PM	Clearside Biomedical Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-22 07:05AM	Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-01-22 07:05AM	Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2022 (GlobeNewswire) -6.58%
Feb-28-22 08:25AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-25-22 07:05AM	Clearside Biomedical to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Thursday, March 10, 2022 (GlobeNewswire) +8.90%
Feb-14-22 04:05PM	Clearside Biomedicals Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference (GlobeNewswire)
Feb-11-22 05:42AM	The past five years for Clearside Biomedical (NASDAQ:CLSD) investors has not been profitable (Simply Wall St.)
Feb-02-22 07:05AM	Clearside Biomedicals Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022 (GlobeNewswire) -6.15%
Dec-21-21 07:05AM	Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD (GlobeNewswire)
Dec-13-21 04:05PM	Clearside Biomedical Added to the Nasdaq Biotechnology Index (GlobeNewswire)

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibney Anthony S	Director	Apr 18 '24	Buy	1.30	93,290	121,277	100,000	Apr 19 09:45 AM
Gibney Anthony S	Director	Apr 17 '24	Buy	1.25	6,710	8,388	6,710	Apr 19 09:45 AM
Chong Ngai Hang Victor	CHIEF MEDICAL OFFICER	Mar 20 '24	Buy	1.60	30,000	48,000	30,000	Mar 20 04:30 PM
WHITMORE BRADFORD T	10% Owner	Feb 07 '24	Buy	1.35	444,444	599,999	4,495,034	Feb 09 01:00 PM
LASEZKAY GEORGE M	CEO	Jan 19 '24	Sale	1.27	18,000	22,860	466,577	Jan 19 06:26 PM
Deignan Charles A.	Chief Financial Officer	Jan 19 '24	Sale	1.28	12,900	16,512	384,662	Jan 19 06:25 PM
WHITMORE BRADFORD T	10% Owner	Nov 01 '23	Buy	0.74	64,366	47,901	4,050,590	Nov 01 04:24 PM
WHITMORE BRADFORD T	10% Owner	Oct 31 '23	Buy	0.73	70,812	51,537	3,986,224	Nov 01 04:24 PM
WHITMORE BRADFORD T	10% Owner	Oct 30 '23	Buy	0.69	600	411	3,915,412	Nov 01 04:24 PM
Hutson Nancy J	Director	Oct 03 '23	Buy	0.86	10,000	8,600	93,000	Oct 04 05:06 PM
Thorp Clay	Director	Sep 25 '23	Buy	0.86	10,000	8,600	40,522	Sep 25 04:34 PM
Humphries William D.	Director	Sep 22 '23	Option Exercise	0.40	22,727	9,091	51,040	Sep 22 04:35 PM
Deignan Charles A.	Chief Financial Officer	Sep 13 '23	Option Exercise	0.40	34,090	13,636	397,562	Sep 13 06:55 PM

Open in Screener

VIGL

Vigil Neuroscience Inc

May 03 • 04:00PM ET

3.03

Dollar change +0.29
Percentage change 10.58	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VIGL Vigil Neuroscience Inc daily Stock Chart

Held by: VTI IWM VXF IWN VTWO IWC VTWV GSSC URTY VTHR

Index	RUT	P/E	-	EPS (ttm)	-2.13	Insider Own	60.34%	Shs Outstand	35.88M	Perf Week	11.81%
Market Cap	113.87M	Forward P/E	-	EPS next Y	-2.32	Insider Trans	0.02%	Shs Float	14.91M	Perf Month	-7.06%
Income	-82.64M	PEG	-	EPS next Q	-0.61	Inst Own	33.92%	Short Float	6.18%	Perf Quarter	13.06%
Sales	0.00M	P/S	-	EPS this Y	-8.33%	Inst Trans	28.17%	Short Ratio	10.55	Perf Half Y	-56.47%
Book/sh	3.24	P/B	0.94	EPS next Y	-0.60%	ROA	-48.43%	Short Interest	0.92M	Perf Year	-64.93%
Cash/sh	3.14	P/C	0.97	EPS next 5Y	-	ROE	-54.13%	52W Range	2.50 - 11.11	Perf YTD	-10.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.96%	52W High	-72.73%	Beta	1.88
Dividend TTM	-	Quick Ratio	10.45	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.20%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	10.45	EPS Y/Y TTM	2.30%	Oper. Margin	0.00%	RSI (14)	53.56	Volatility	9.66% 8.97%
Employees	69	Debt/Eq	0.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	16.75
Option/Short	No / Yes	LT Debt/Eq	0.11	EPS Q/Q	-19.06%	Payout	-	Rel Volume	0.82	Prev Close	2.74
Sales Surprise	-	EPS Surprise	-6.80%	Sales Q/Q	-	Earnings	Mar 26 BMO	Avg Volume	87.31K	Price	3.03
SMA20	3.34%	SMA50	-1.66%	SMA200	-33.87%	Trades		Volume	71,456	Change	10.58%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$13 → $4
Oct-18-23	Initiated	JMP Securities	Mkt Outperform	$23
Mar-31-23	Initiated	Mizuho	Buy	$15
Sep-16-22	Initiated	Wedbush	Outperform	$19
Aug-29-22	Initiated	H.C. Wainwright	Buy	$24
Feb-01-22	Initiated	Stifel	Buy	$24
Feb-01-22	Initiated	Morgan Stanley	Equal-Weight	$17
Feb-01-22	Initiated	Jefferies	Buy	$20
Feb-01-22	Initiated	Guggenheim	Buy	$23

Apr-17-24 04:05PM	Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-26-24 01:53PM	VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023 (InvestorPlace) -7.00%
07:05AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:05AM	Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer (GlobeNewswire) +9.18%
Mar-13-24 07:05AM	Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting (GlobeNewswire)
07:05AM	Loading…
Mar-12-24 07:05AM	Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire) -5.99%
Mar-06-24 04:25PM	Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024 (GlobeNewswire)
Feb-29-24 04:05PM	Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024 (GlobeNewswire)
Feb-07-24 04:05PM	Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 04:30PM	Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones (GlobeNewswire)
Nov-22-23 04:05PM	Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire) -9.17%
Nov-16-23 04:05PM	Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE (GlobeNewswire)
Nov-07-23 07:05AM	Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.34%
Oct-18-23 09:52AM	Arm initiated, SQM downgraded: Wall Street's top analyst calls (The Fly)
Oct-17-23 07:05AM	Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease (GlobeNewswire) +6.65%
04:01PM	Loading…
Oct-05-23 04:01PM	Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (GlobeNewswire)
Sep-26-23 07:05AM	Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP (GlobeNewswire)
Sep-11-23 12:00PM	Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting (GlobeNewswire)
Sep-08-23 04:05PM	Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program (GlobeNewswire)
07:05AM	Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-08-23 07:05AM	Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 04:05PM	Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer (GlobeNewswire) -8.33%
Jun-01-23 07:00AM	Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference (GlobeNewswire)
May-10-23 07:00AM	Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-09-23 07:00AM	Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors (GlobeNewswire)
May-08-23 08:30AM	Vigil Neuroscience (NASDAQ:VIGL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
07:08AM	Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (GlobeNewswire)
Mar-30-23 07:00AM	Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101 (GlobeNewswire)
Mar-22-23 07:00AM	Vigil Neuroscience to Present at Stifel 2023 CNS Days (GlobeNewswire) +10.82%
Mar-21-23 07:00AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
04:00PM	Loading…
Mar-02-23 04:00PM	Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire)
Jan-03-23 07:00AM	Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-22 04:01PM	Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team (GlobeNewswire)
Dec-14-22 04:01PM	Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP (GlobeNewswire) +6.66%
Nov-29-22 05:23AM	We Think Vigil Neuroscience (NASDAQ:VIGL) Can Afford To Drive Business Growth (Simply Wall St.)
Nov-28-22 07:00AM	Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022 (GlobeNewswire) +11.46%
Nov-10-22 07:00AM	Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -23.86%
Nov-07-22 07:00AM	Vigil Neuroscience to Present at Upcoming Investor Conferences (GlobeNewswire) +10.07%
Nov-02-22 12:43PM	Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological Disease (Benzinga) -12.04%
07:00AM	Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP (GlobeNewswire)
Nov-01-22 07:00AM	Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP (GlobeNewswire)
Oct-12-22 07:58AM	7 Short-Squeeze Stocks to Buy for Contrarian Investors (InvestorPlace) +37.01%
Sep-14-22 09:55AM	Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know (Zacks)
Sep-01-22 07:00AM	Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-29-22 09:55AM	How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133% (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to Trade (Zacks) +8.34%
07:00AM	Vigil Neuroscience Announces $75 Million Private Placement Financing (GlobeNewswire)
Aug-08-22 07:00AM	Vigil Neuroscience Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-22 07:00AM	Vigil Neuroscience to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-01-22 07:00AM	Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-28-22 07:00AM	Vigil Neuroscience Strengthens Board of Directors with Appointment of Suzanne Bruhn, Ph.D. (GlobeNewswire)
Jun-09-22 09:58AM	7 No-Brainer Biotech Stocks to Add to Your Buy List (InvestorPlace)
Jun-07-22 07:00AM	Vigil Neuroscience Expands VGL101 Phase 1 Trial to Australia (GlobeNewswire) +10.20%
Jun-01-22 07:00AM	Vigil Neuroscience to Present at 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-22 07:00AM	Vigil Neuroscience Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-20-22 07:00AM	Vigil Neuroscience Expands Leadership Team and Board of Directors (GlobeNewswire)
Apr-08-22 12:33PM	We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-25-22 06:30AM	Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire) -6.94%
Mar-21-22 07:00AM	Vigil Neuroscience to Present at Stifel 2022 CNS Days (GlobeNewswire) -24.37%
Mar-03-22 04:05PM	Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting (GlobeNewswire)
Jan-27-22 01:46PM	Wall Street gyrations may thwart deal closings, IPO outlook (American City Business Journals)
05:30AM	New Year, Fresh Stocks: 3 IPOs That Joined the Market in January (Motley Fool)
Jan-11-22 04:01PM	Vigil Neuroscience Announces Closing of Initial Public Offering (GlobeNewswire)
Jan-06-22 11:07PM	Vigil Neuroscience Announces Pricing of Initial Public Offering (GlobeNewswire)

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Magovcevic-Liebisch Ivana	President and CEO	Nov 20 '23	Buy	3.75	4,000	15,000	207,687	Nov 20 06:34 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CLSD

Clearside Biomedical Inc

VIGL

Vigil Neuroscience Inc

Upgrade your FINVIZ experience